Clinical trials: Metastatic Malignant Neoplasm to Brain
Triple-Negative Breast Cancer (TNBC), Brain Metastases
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab…
- Trial name
- BALISTA (NCT06793332)
- Testing
- Ivonescimab Combined With TROP2 ADC
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fudan University
NSCLC Stage IV, Brain Metastases
SRS Sequential Sindilimab in Brain Metastasis of NSLSC
A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab
- Conditions
- NSCLC Stage IV, Brain Metastases, SRS, Sintilimab
- Trial name
- NCT04180501
- Testing
- SRS sequential sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xiaorong Dong
Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC
The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with Perilesional edema in non-small cell lung cancer.
- Trial name
- Rvision-001 (NCT04147728)
- Testing
- Anlotinib, Stereotactic Radiosurgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Phase II Clinical Trial, Ninety-six Histologically Confirmed NSCLC Patients With BM
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients
Background: Whole-brain radiotherapy (WBRT) is the standard treatment for multiple brain metastases (BM), in NSCLC patients who are not candidates for treatment with stereotactic radiation body therapy.
- Conditions
- Phase II Clinical Trial, Ninety-six Histologically Confirmed NSCLC Patients With BM, Randomized 1:1 to Received TN Plus WBR or Only WBR, ICPFS Evaluated by Two Blinded and Independent Radio-oncologist With MRI
- Trial name
- NCT04338867
- Testing
- Whole-brain radiotherapy
- Where
- Mexico
- Volunteers
- 96 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Brain Metastases
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).
- Trial name
- NCT02031237
- Testing
- Single Fraction Stereotactic Radiosurgery (SRS), Fractionated Whole Brain Radiation Therapy (WBRT), Fractionated Stereotactic Radiation Therapy (FSRT)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Michigan Rogel Cancer Center
Malignant Melanoma
Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
The purpose of this study is to determine wether cobimetinib + vemurafenib combination treatment is effective in the treatment of BRAFV600-mutated melanoma patients with brain metastasis
- Trial name
- CONVERCE (NCT02537600)
- Testing
- Cobimetinib + Vemurafenib combination treatment
- Where
- 17 sites in France
- Volunteers
- 43 people
- Sponsor
- Center Eugene Marquis
TNBC, Brain Metastasis
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases.
- Trial name
- NCT07623577
- Testing
- Sacituzumab Tirumotecan (Sac-TMT), bevacizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic, Brain Metastases, Adult
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
GENCONCOR-1 study is translational research aimed to investigate the concordance of the molecular genetic profile of the primary tumor and brain metastases (BM) of colorectal cancer (CRC).
- Conditions
- Colorectal Cancer Metastatic, Brain Metastases, Adult, Ras (KRAS or NRAS) Gene Mutation, BRAF Gene Mutation
- Trial name
- GENCONCOR-1 (NCT06449989)
- Testing
- Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Neoplasms, Leptomeningeal Metastasis
Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
The main purpose of this study is to investigate the efficacy of bevacizumab, etoposide and cisplatin in treating breast cancer patients with central nervous system metastasis (including brain parenchymal and leptomeningeal…
- Conditions
- Breast Neoplasms, Leptomeningeal Metastasis, Brain Metastases
- Trial name
- NCT01281696
- Testing
- Bevacizumab, etoposide, cisplatin, Intrathecal methotrexate
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Breast Neoplasms, Neoplasm Metastasis
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions…
- Trial name
- NCT01441596
- Testing
- Vinorelbine, Investigator's choice of treatment, afatinib
- Where
- 40 sites in United States, Canada and 6 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Brain Oligometastatic, Non-small Cell Lung Cancer
Brain Oligometastasis in NSCLC
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized.
- Trial name
- OligoLung (NCT07389642)
- Testing
- Standard treatments / multiple strategies
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Bordeaux
Brain Metastases, Adult, Central Nervous System Metastases
Focal Intraoperative Radiotherapy of Brain Metastases
Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors.
- Trial name
- NCT03789149
- Testing
- Intraoperative Radiotherapy
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- AC Camargo Cancer Center
Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases
Palbociclib and Pembrolizumab In Central Nervous System Metastases
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: Palbociclib alone (Cohort 1) The…
- Conditions
- Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
- Trial name
- NCT02896335
- Testing
- Palbociclib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Cancer Metastatic, Brain Metastases
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases
This is a prospective, single-center observational clinical study aimed at the efficacy and safety of radiotherapy combined with PD-1 inhibitors and chemotherapy in the treatment of Chinese patients with symptomatic NSCLC with…
- Trial name
- NCT05638425
- Testing
- Radiotherapy combined with PD-1 inhibitors
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiangya Hospital of Central South University
Breast Cancer Stage IV
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
- Trial name
- TUXEDO-2 (NCT05866432)
- Testing
- Datopotamab deruxtecan
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Conditions
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Trial name
- NCT07511933
- Testing
- 86-Gallium PSMA PET/CT
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Brain Tumor, Non Small Cell Lung Cancer
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA…
- Trial name
- LIMITLESS (NCT05317858)
- Testing
- Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- InSightec
Neoplasm Metastasis
Dexamethasone for Palliation - Brain Metastases
Brain metastases occur when cancer cells from the initial tumour site (for example, lung or breast) spread to the brain. This develops in approximately 10% - 30% of adults with cancer.
- Trial name
- NCT00188864
- Testing
- dexamethasone
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of nivolumab when giving together with stereotactic radiosurgery or whole brain radiotherapy with or without ipilimumab and to see how well they work in treating…
- Trial name
- NCT02696993
- Testing
- Cognitive Assessment, Ipilimumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center